Cardorite-10 Zim Laboratories reduce the amount of cholesterol (3 blisters x 10 tablets)
Dosage form Box of 3 blisters x 10 tablets
Specifications Rosuvastatin
Ingredient High blood fat, high blood cholesterol
Ingredient
| Composition information | Content |
| Rosuvastatin | 10mg |
Uses
indications
Cardorite - 10 is indicated in the following cases:
Supplement for a diet to reduce total cholesterol, LDL - Cholesterol, APOB, NonHDL - C, and Triglyceride (TG) and increase HDL - C in primary hypercholesterol patients (Heterogeneous and non -family -free family), and mixed blood lipid disorders (Fredrickson type IA and IIB).
Support for diet to treat patients with high serum levels (Fredrickson type IV).
To reduce LDL - C, total cholesterol, and apob in patients with primary blood cholesterol hyperplasia, as another supportive drug for lipid lowering treatments (for example: decanted LDL in the blood) or if such treatment is not available.
Use in conjunction with adjustment of diet for patients with beta lipoprotein disorders (increased blood lipoprotein III).
Prevention of primary cardiovascular disease. In patients without clinical coronary artery disease but increases the risk of cardiovascular disease, including over 50 for men and over 60 for women, HSCRP ≥ 2 mg/l and at least one risk factor for cardiovascular disease such as hypertension, LDL - C, smoking or family history of people with early coronary artery disease, Rosuvastatin is only risked to reduce the risk Interventions for blood vessels.
Pharmacokology
Rosuvastatin is a selective inhibitor and competition for HMG - COA elimination enzyme, a limited enzyme limiting the metabolism speed of Coenzyme A 3 - hydroxy - 3 - methylglutaryl into Mevalonate - Pre -quality of cholesterol. The main effect of rosuvastatin is the liver. Rosuvastatin increases the number of liver LDL receptors on the cell surface, increases the absorption and metabolism of LDL and inhibits the synthesis of VLDL in the liver thus reducing the total amount of VLDL and LDL.
Rosuvastatin reduces total cholesterol (TC - Total Cholesterol), LDL - C, APOB, and NonHDL - C (HDL - C Reduce) in patients with primary hypercholular hypermens with homosexuality and heterozygous (FH), cholesterol hypercasting without family properties, and mixed blood lipid disorders. Rosuvastatin also reduces the TG and increases HDL - C. Rosuvastatain reduces TC - Total Cholesterol, LDL - C, VLDL - Cholesterol (VLDCL - C), APOB, NonHDL - C and TG, and increases HDL - C in patients with hyperlly triglycerides.
Dynamic pharmacokinetics
absorption
Birth of rosuvastatin is about 20%. The concentration of rosuvastatin in plasma is not different after taking the evening or morning medication. The reduction of LDL - C takes place significantly even if there is or not using rosuvastatin with food, and regardless of the daily use of medication.
distribution
The average distribution of rosuvastatin in a durable state is about 134 L. Rosuvastatin binds 88% to plasma protein, mainly albumin. This link is reversible and depends on plasma concentrations.
transformation
Rosuvastatin is not metabolized much, about 10% of the dose with radioactive isotope is found in the form of metabolites. The main metabolites are N - Desmethyl Rosuvastatin, created mainly by Cytochrom P450 2C9, and invitro studies have shown that N - Desmethyl Rosuvastatin has about one six to half of the HMG - CoA enzyme that inhibits the activity of Rosuvastatin.
Elimination
After drinking, rosuvastatin and its metabolites are mainly excreted in feces (90%). The sale time of rosuvastatin (T1/2) is about 19 hours.
Before taking Cardorite-10 Zim Laboratories reduce the amount of cholesterol (3 blisters x 10 tablets)
How to use
oral tablets. Take the tablet with a glass of water.
Before starting treatment, patients need to follow a standard diet to reduce cholesterol and maintain during medication. The drug can be used at any time of the day, used during meals or away from meals.
Dosage
Adults
The dose for adults is from 5 to 40 mg. In case of prevention of primary cardiovascular disease, the dose is 20 mg/day.
The normal starting dose is 5 or 10 mg once a day. For patients with primary hypercholesterolemia hyperconders, the starting dose is 20 mg once a day.
Dosage must be individualized according to the patient's treatment and response goals. Selecting the starting dose level to consider the patient's cholesterol levels and cardiovascular risks as well as the risk of unwanted effects.
After 2 to 4 weeks of starting or adjusting dose dose, the test is needed to monitor the blood lipid level and the adjustment to the next dose level can be done after 4 weeks. Due to the frequency of unwanted effects reported at a dose of 40 mg compared to lower doses, the adjustment of the dose to the maximum dose of 40 mg should only be considered when the patient has a serious hypercoles (especially with hypercast blood cholesterol) without achieving treatment effects at a dose of 20 mg, and patients who are monitored regularly.
Children
In patients with hypercondic hypertension hyperlested hypertension, the recommended dose is from 5 to 10 mg oral 1 time/day in patients from 8 to under 10 years old and 5 to 20 mg oral 1 time/day in patients from 10 to 17 years old.
In patients with hyperconded hypertension with homozygous, recommended dose is 20 mg oral 1 time/day in patients from 7 to 17 years old.
Asian patients
In patients with Asians, it is necessary to consider the starting dose of 5 mg once a day due to increased blood rosuvastatin levels. In case of failure to achieve treatment goals may consider increasing the dose to 20 mg/day.
Elderly
The starting dose recommended for people over 70 years old is 5 mg once a day. It is not necessary to conduct other measures to adjust the dose by age.
Patients with liver failure
Rosuvastatin concentration in the blood does not increase in patients with Pugh ≤ 7. However, in patients with Child Pugh 8 and 9, Rosuvastatin concentration in the blood increases.
In these patients, it is necessary to conduct kidney function assessment. There is no clinical data on the use of drugs in patients with PUGH score over 9. The drug is contraindicated in patients with progressive liver disease.
Patients with renal failure
There is no need to change the dose for patients with mild to moderate renal failure. For patients with average renal failure (CLCR
Used in combination with other drugs
The risk of muscle diseases (including muscle pepper) increases when taking the drug simultaneously with some drugs that increase the concentration of rosuvastatin in the blood (such as ciclosporin and some protease inhibitors include a combination of ritonavir with Atazanavir, Lopinavir, and/or Tipranavir) and Gemfibrozil, other Fibrat blood medications, other fibrine blood groups, niacin fibratoly High doses (> 1 g/day), Colchicin. In case it may be necessary to consider other treatments and if necessary, it may temporarily stop using rosuvastatin. In case of compulsory combination of these drugs with rosuvastatin, be careful to consider the benefits and risks and adjust the dose of rosuvastatin. The maximum limit of rosuvastatin dose when coordinated with acacanavir, Atazanavir and Ritonavir, Lopinavir and Ritonavir is 10 mg once a day.
Simultaneous use of statin lipid medications with HIV and hepatitis C (HCV) can increase the risk of muscle damage, the most serious muscle, kidney damage leading to kidney failure and may be fatal.
Note: The above dose is for reference only. Specific dosage depends on the condition and level of progression of the disease. For a suitable dose, you need to consult a doctor or medical specialist.What do
do when overdose? In the event of an overdose, patients need to be treated with symptoms and take supportive measures if necessary and should monitor liver and ck function. The dialysis does not significantly increase the clearance of rosuvastatin.
In an emergency, call the 115 emergency center immediately or go to the nearest local health station.
What to do when you forget 1 dose? However, if the time to relax with the next dose is too short, skip the dose and continue the calendar of the drug. Do not use double dose to compensate for missed dose.
Side Effects
When using the drug, there are common unwanted effects (ADR) such as:
rosuvastatin is generally tolerated well. The side effects are usually light and transient. In clinical studies of 10,275 patients, 3.7 % must stop taking the drug due to side effects. When using rosuvastatin may have muscle pain, constipation, weakness, abdominal pain, and nausea, cognitive impairment (such as memory loss, confusion ...), hyperglycemia, HBA1C.
The following unwanted effects are listed according to the frequency and organ system.
The frequency of unwanted effects is ranked according to the following criteria: Common (1/100 to
Warnings
Before using the drug you need to read the instructions carefully and refer to the information below.
Contraindicated
Cardorite - 10 contraindications in the following cases:
Dosage level of 40 mg is contraindicated in patients: medium renal failure (Creatinine clearance Be cautious when using
Effects on the kidneys
proteinuria, detected by test strips and most of the renal tubules, have been reported to patients using high -dose rosuvastatin, especially 40 mg, most of them occur transient or interrupted. Proteinuria shows signs of acute or progressive kidney disease. The frequency of reporting serious kidney diseases is higher for a dose of 40 mg. Need to assess kidney function when regular monitoring patients when taking the dose of 40 mg.
Effects on skeletal system
Effects on musculoskeletal systems such as muscle pain, muscle disease and rare muscle pepper have been reported when using rosuvastatin at all special doses, the dose of over 20 mg. Very few cases of muscle pattern have been reported when using ezetimibe combined with HMG - CoA Reductase enzyme inhibitors, so be careful when used in combination. The frequency of pattern is related to the use of rosuvastatin higher at the dose of 40 mg.
Patients need to be tested for liver enzyme before starting treatment with rosuvastatin and in case of clinical indications for testing later.
Increased risk of muscle damage when using rosuvastatin simultaneously with the following drugs: Gemfibrozil, other fibrat blood cholesterol medications, high -dose niacin (> 1 g/day), Colchicin.
Consider monitoring Creatin Kinase (CK) in the case of
Before treatment, CK tests should be conducted in the following cases: impaired renal function, hypothyroidism, self -history or family history of genetic muscle disease, a history of muscle disease due to the use of statin or fibrat before, a history of liver disease and/or drinking lots of alcohol, elderly patients (> 70 years old) with risk factors for muscle pattern, special possibility of drug interactions and some special patients. In these cases, the benefits/risks should be considered and monitor patients clinically when treated with statin. If the results of CK test> 5 times the upper limit of normal levels, do not start treatment with statin.
During statin treatment, patients need to notify when there are muscle manifestations such as muscle pain, muscle stiffness, muscle weakness, ... When these manifestations, patients need to do CK test to take appropriate interventions.
Effects on the liver
Be careful when taking the drug with patients who drink a lot of alcohol and/or have a history of liver disease. The testing of liver function is recommended before and after 3 months of starting treatment with rosuvastatin. It is necessary to take the drug or reduce the dose when the concentration of transaminase in the blood is tripled by the above limit. The frequency of reporting of dangerous liver diseases (mainly liver transaminase increases) higher than the dose of 40 mg.
In patients with secondary hypercholesterolemia caused by hypothyroidism or nephrotic syndrome, it is necessary to treat these diseases before starting Rosuvastatin.
Race
Dynamic pharmacokinetic studies show the increase in blood rosuvastatin levels in Asian people when taking the drug compared to white skin patients.
Pregnancy and lactation
Atherosclerosis is a chronic process and the stopping of blood lipid medication during pregnancy has little effect on long -term treatment results for increased primary cholesterol. Cholesterol and other substances of cholesterol biosynthesis are essential for fetal development (including sterol synthesis and cell membranes). Because HMG - Coa Reductase inhibitors reduce cholesterol synthesis and the ability to synthesize the biological derivatives of cholesterol, it can harm the fetus for pregnant women. Therefore, HMG - CoA Reductase inhibitors are contraindicated during pregnancy and lactation.
Rosuvastatin is only used for women during childbirth when the patient has no intention of pregnancy and has been notified about the risks may be encountered.
If a patient is pregnant during this medication, the treatment should be stopped immediately and the patient must be notified of possible risks to the embryo.
Lactose tolerance
Patients with genetic problems in lactose tolerance, lactase lactase lack of lactase or malposive glucose - galactose should not use this drug.
Protease inhibitors
Simultaneous use of statin lipid medications with HIV and hepatitis C (HCV) can increase the risk of muscle damage, the most serious muscle, kidney damage leading to kidney failure and may be fatal.
Interstitial lung disease
Some cases of interstitial lung disease have been reported when using statins, especially for long -term use. Signs include: shortness of breath, health impairment (fatigue, weight loss and fever). If the patient is suspected of interstitial lung disease, it is necessary to stop using statin.
pancreatic diabetes
Some evidence suggests that statins may increase blood sugar. However, the effect of reducing the risk of the circuits of statins is superior to the risk of hyperglycemia, so there is no need to stop using statins. Patients with risk (thrilling blood sugar from 5.6 to 6.9 mmol/l, body mass index (BMI)> 30 kg/m, increased triglycerides, hypertension) should be monitored both clinically and test indicators according to treatment instructions.
Children
Review height, weight, body mass index (BMI) and secondary characteristics of gender maturity in children from 6 to 17 years old using Rosuvastatin are limited for 2 years. After 2 years, there is no influence on height, weight, BMI or mature gender detected.
The effect of the drug on driving and operating machinery
The studies on the effects of the drug on driving and operating machinery have not been conducted. However, according to pharmacological effects, the drug has little effect on this ability. Caution should be careful when driving and operating machinery during medication because it can be dizzy.
Use drugs for women during pregnancy and lactation
Pregnancy
Not for pregnant women.
Breastfeeding period
Do not use for breastfeeding women.
Drug interaction
drug interactions can affect the activity of the drug or cause side effects.
Patients should notify the doctor or pharmacist a list of the drugs and functional foods you are using. Do not use or increase or decrease the dose of the drug without the guidance of a doctor.
Transport protein inhibitors
Rosuvastatin is the substrate of some transport proteins including OATP1B1 and BCRP. Simultaneous use of rosuvastatin with these inhibitors of these transport proteins can increase the level of rosuvastatin in the blood and increase the risk of muscle diseases.
ciclosporin
Concomitance simultaneous use of rosuvastatin and ciclosporin, the AUC value of rosuvastatin is 7 times higher than those who do not use combined so contraindicated combination of these two drugs together. Simultaneous use does not affect the concentration of ciclosporin.
Protease inhibitors
Increased blood rosomastatin levels have been reported in patients with simultaneous use of rosuvastatin with protease inhibitors in combination with ritonavir. The simultaneous use of statin lipid medications with HIV and hepatitis C (HCV) can increase the risk of muscle damage, the most serious muscle, kidney damage leads to kidney failure and can be fatal.
gemfibrozil and other lipid medications
Increased risk of muscle damage when using rosuvastatin simultaneously with the following drugs: Gemfibrozil, other fibrat blood cholesterol medications.
ezetimibe
Simultaneous use of Rosuvastatin 10 mg and Ezetimibe 10 mg increases the AUC Rosuvastatin 1.2 times in patients with hypercholesterol.
antacid
Simultaneous use of rosuvastatin with an aluminum -containing antacid -containing antacid -hydroxyd -shaped antacid that reduces the blood's rosmastatin levels by 50%. Utacid should be used for 2 hours after using rosuvastatin.
erythromycin
Simultaneous use of 2 drugs reduces 20% AUC and 30% CMAX of RosuVastatin. This interaction may be due to erythromycin increasing intestinal motility.
Other interactions
Increased risk of muscle lesions when using rosuvastatin simultaneously with high -dose niacin drugs (> 1 g/day), colchicin.
Rosuvastatin interacts with alcohol, acid neutralization in the stomach, birth control pills, otraconazole, enzymes (cholestin, supplements), warfarin.
The dose adjustments
When it is necessary to adjust the dose, the starting dose of rosuvastatin is 5 mg once a day if it is likely to increase AUC about 2 times or higher. The maximum dosage of rosuvastatin should be adjusted to amount of rosuvastatin into the body without an overdose of 40 mg used once a day when not in use with other drugs, for example 20 mg of rosuvastatin with gemfibrozil (an increase of 1.9 times), and 10 mg of rosuvastatin in combination with Ritonavir/Atazanavir (an increase of 3.1 times).
The influence of rosuvastatin on drugs used with
Vitamin K anti -vitamin k
Similar to other HMG - Coa Reductase inhibitors, when starting to treat or adjust the rodgastatin dose in patients who use vitamin K anti -vitamin K (such as warfarin or other Coumarin anticoagulants) can increase international normal chemical ratio (INR). Stop or reduce the dose of rosuvastatin may reduce the INR. In these cases, it is necessary to apply appropriate Inr control measures.
Oral contraceptive/hormone replacement contraceptives used simultaneously rosuvastatin and oral contraceptives increase the AUC Ethinyl Estradiol and Norgestrel, respectively 26 and 34%respectively. Increasing the concentration of these substances in the blood should be considered when choosing oral contraceptive dose. There is no sufficient dynamic data in patients using rosuvastatin simultaneously and hormone replacement therapy and therefore cannot exclude the same effect of rosuvastatin. However, the combination of rosuvastatin and hormone replacement therapy has been widely used in women participating in clinical trials and has been well tolerated
digoxin
Based on drug interactive studies, there is no clinical interaction between digoxin and rosuvastatin.
Fusidic acid
Interactive studies between rosuvastatin and fusidic acid have not been conducted. Like other statins, muscle -related effects, including muscle pepper, have been reported on after -sales reports with rosuvastatin and fusidic acid when used simultaneously.
Therefore, simultaneous use of fusidic acid and rosuvastatin are not recommended. If possible, it is advisable to stop using rosuvastatin. If required to be used simultaneously, it is necessary to closely monitor patients.
Children
Research on drug interactions has only been conducted in adults. The level of influence of the above drug interactions in children is not known. Notify the doctor about all drugs that are in use, including non -prescribing drugs, nutritional supplements or herbal products. It is also advisable to notify the doctor while using caffeine or alcoholic beverages, smoking or banned drugs. These can affect the treatment process. Check before stopping or starting any drug.
Storage
Leave a cool place, avoid light, temperatures below 30⁰C.
To be out of reach of children, read the instructions carefully before use.
Other drugs
- Advagraf
- HIRUDOID CREAM
- IMUNOVIR 500MG TABLETS
- Neoclarityn
- OLICLINOMEL N4-550E EMULSION FOR INFUSION
- Relvar Ellipta
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions